{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:27:35Z","timestamp":1778297255915,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41409-024-02432-x","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T09:01:57Z","timestamp":1728032517000},"page":"79-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of daratumumab on collection and engraftment in multiple myeloma patients undergoing hematopoietic stem cell mobilization with G-CSF plus on-demand plerixafor"],"prefix":"10.1038","volume":"60","author":[{"given":"Giuseppe","family":"Bertuglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Casson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-9296","authenticated-orcid":false,"given":"Jacopo","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"D\u2019agostino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"De Philippis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-9492","authenticated-orcid":false,"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-541X","authenticated-orcid":false,"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2432_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1.","journal-title":"Lancet"},{"key":"2432_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/nejmoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho J, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313. https:\/\/doi.org\/10.1056\/nejmoa2312054.","journal-title":"N Engl J Med"},{"key":"2432_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014.","journal-title":"Ann Oncol"},{"key":"2432_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, H\u00fcbel K, Kr\u00f6ger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for blood and marrow transplantation. Bone Marrow Transplant. 2014;49:865\u201372. https:\/\/doi.org\/10.1038\/bmt.2014.39.","journal-title":"Bone Marrow Transplant"},{"key":"2432_CR5","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","volume":"106","author":"C Hulin","year":"2021","unstructured":"Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib\/thalidomide\/dexamethasone in the phase III CASSIOPEIA study. Haematologica. 2021;106:2257\u201360. https:\/\/doi.org\/10.3324\/haematol.2020.261842.","journal-title":"Haematologica"},{"key":"2432_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2450\/BloodTransfus.667","volume":"22","author":"A Zappaterra","year":"2024","unstructured":"Zappaterra A, Civettini I, Cafro AM, Pezzetti L, Pierini S, Anghilieri M, et al. Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients. Blood Transfus. 2024;22:328\u201337. https:\/\/doi.org\/10.2450\/BloodTransfus.667.","journal-title":"Blood Transfus"},{"key":"2432_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3324\/haematol.2022.281610","volume":"108","author":"K Lemonakis","year":"2023","unstructured":"Lemonakis K, T\u00e4tting L, Lisak M, Carlson K, Crafoord J, Blimark C, et al. Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients. Haematologica. 2023;108:610\u20134. https:\/\/doi.org\/10.3324\/haematol.2022.281610.","journal-title":"Haematologica"},{"key":"2432_CR8","doi-asserted-by":"publisher","first-page":"340.e1","DOI":"10.1016\/j.jtct.2023.02.013","volume":"29","author":"A Thurlapati","year":"2023","unstructured":"Thurlapati A, Roubal K, Davis JA, Shah SZ, Smith D, McGann M, et al. Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real- world experience. Transplant Cell Ther. 2023;29:340.e1\u2013340.e4. https:\/\/doi.org\/10.1016\/j.jtct.2023.02.013.","journal-title":"Transplant Cell Ther"},{"key":"2432_CR9","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","volume":"64","author":"E Eleutherakis Papaiakovou","year":"2023","unstructured":"Eleutherakis Papaiakovou E, Terpos E, Kanellias N, Magdalini M, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2023;64:2140\u20137. https:\/\/doi.org\/10.1080\/10428194.2023.2253479.","journal-title":"Leuk Lymphoma"},{"key":"2432_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-142115","volume":"136","author":"S Manjappa","year":"2020","unstructured":"Manjappa S, Fox R, Reese J, Firoozamand A, Schmikla H, Nall S, et al. Impact of daratumumab on stem cell collection, graft composition and engraftment among multiple myeloma patients undergoing autologous stem cell transplant. Blood. 2020;136:35\u201337. https:\/\/doi.org\/10.1182\/blood-2020-142115.","journal-title":"Blood"},{"key":"2432_CR11","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1182\/blood-2019-131380","volume":"134","author":"AS Al Saleh","year":"2019","unstructured":"Al Saleh AS, Sidiqi MH, Gertz MA, Muchtar E, Lacy MQ, Warsame RM, et al. Delayed neutrophil engraftment in patients receiving daratumumab as part of their first induction regimen for multiple myeloma. Blood. 2019;134:4505\u20134505. https:\/\/doi.org\/10.1182\/blood-2019-131380.","journal-title":"Blood"},{"key":"2432_CR12","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1182\/blood-2021-149028","volume":"138","author":"S Chhabra","year":"2021","unstructured":"Chhabra S, Callander NS, Costa LJ, Kaufman JL, Laubach JP, Sborov DW, et al. Stem cell collection with daratumumab (DARA)-based regimens in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts) in the Griffin and Master Studies. Blood. 2021;138:2852. https:\/\/doi.org\/10.1182\/blood-2021-149028.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02432-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:03:02Z","timestamp":1736510582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02432-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2432"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02432-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RM has received honoraria from Sanofi, Pfizer, Amgen, Takeda, Celgene, Janssen; has served on the advisory boards for Bristol Myers Squibb, Amgen, Takeda, Celgene, Janssen; has received consultancy fees from Sanofi, Takeda. FG has received honoraria from AbbVie, Roche, Takeda, Pfizer, Sanofi, Celgene\/Bristol Myers Squibb, Janssen, GlaxoSmithKline; has served on advisory board for Abbvie, Roche, Takeda, Pfizer, Sanofi, Celgene\/Bristol Myers Squibb, Oncopeptides, Janssen\u00b8 GlaxoSmithKline. MD has received honoraria from GlaxoSmithKline, Sanofi, and Janssen; has served on the advisory boards for GlaxoSmithKline, Sanofi, Adaptive Biotechnologies, and Bristol Myers Squibb. SO has received honoraria from Abbvie, Takeda, Celgene\/Bristol Myers Squibb, Amgen; has received consultancy fees from Janssen, Amgen, Adaptive Biotechnologies. AL has received honoraria from Janssen, GlaxoSmithKline, Menarini, Pfizer, Sanofi; has served on the advisory board for Janssen, GlaxoSmithKline, Menarini, Pfizer, Sanofi. GB has received honoraria from Bristol Myers Squibb, Janssen, Novartis, Jansen; has received consultancy fees from Bristol Myers Squibb, Janssen, Novartis. BB has received honoraria from Amgen, Janssen, Novartis, BeiGene, Bristol Myers Squibb, GlaxoSmithKline, Jazz Pharmaceuticals, AstraZeneca, Incyte; has served on advisory boards for Amgen, Jazz Pharmaceuticals. AS has received honoraria from Eisai, Pfizer, Gilead, Servier, Celgene\/Bristol Myers Squibb, Bayer, Merck MSD, Roche, Abbvie, Amgen; AstraZeneca; Eli Lilly; Sandoz; Novartis; has served on the advisory board for Eisa, Pfizer, Gilead, Servier, Bristol Myers Squibb, Bayer, Merck MSD; has received consultancy fees from Incyte, Sanofi. SB has received honoraria from Celgene, Amgen, Janssen, Bristol Myers Squibb; has served on the board of directors or advisory committees for Celgene, Amgen, Janssen, GlaxoSmithKline, Sanofi, Pfizer; has received consultancy fees from Janssen, Takeda, Celgene, Bristol Myers Squibb. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee or institutional review boards at each of the participating centers (Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino and IRCCS Humanitas Research Hospital). All participants were provided with comprehensive information about the study. Written informed consent was obtained from all participants prior to their inclusion in the study. Personal data were collected and stored in a secure and anonymized manner to ensure participants\u2019 confidentiality and privacy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}